Every other psychedelic shows you more.This one shows you less.
- 5-HT1A
- Non-Visual
- Minutes
Not all psychedelics are the same
Psilocybin, LSD, ayahuasca — they alter perception. They produce imagery. They surface material. They can give you a new way to tell your story.
5-MeO does none of that. Time, space, and the sense of being a self located somewhere, looking out — these are not altered. They are briefly suspended. Researchers who study it call the resulting state deconstructed consciousness.
Every other tool works on the identity. It gives you distance from it, insight into it, a better version of it. 5-MeO does something categorically different: it briefly removes the assumption the identity is standing on — that there is a you in here and a world out there.
That assumption is where the whole structure begins. It is also the one thing no amount of work has ever reached.
Less story. Less identity. Less separation. Not more of you. Less of what was never you.
This is not a trip
No cosmic visuals. No spirit animals. No messages from your childhood.
- No imagery to interpret afterward
- No narrative, no symbolism, no message
- The assumption of separation, briefly suspended
- The operation that builds the self, briefly offline
This is not a psychedelic trip. It is the undoing of the one who trips.
What makes 5-MeO unique
Non-Visual
5-MeO binds preferentially to the 5-HT1A serotonin receptor. Psilocybin and LSD act primarily at 5-HT2A — the receptor where visual content originates. Different receptor. Different mechanism. Nothing to see.
Fast-Acting
Inhaled, the effects begin within seconds and resolve within ten to thirty minutes. Rapidly metabolised, and it clears fully. No long descent.
Naturally Occurring
5-MeO-DMT occurs in certain plants, in the secretion of one toad species, and has been detected in trace amounts in mammalian tissue. It is not exotic chemistry. It is a close structural relative of serotonin.
The science behind the substance
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a tryptamine — structurally, a close relative of serotonin.
Its distinguishing feature is receptor selectivity. It binds the 5-HT1A serotonin receptor with several hundred times the affinity it has for 5-HT2A.1Psilocybin and LSD work primarily through 5-HT2A. That is where the visual content comes from.
This is not a minor difference. It is the mechanical reason there is nothing to see, nothing to narrate, and nothing to interpret afterward.
An exploratory EEG study of the 5-MeO state, conducted in naturalistic settings, found reductions in alpha and posterior beta power — a signature consistent with a brain in which top-down predictive models are temporarily inhibited.2Those are the models that assemble a stable world, and a stable self standing separately inside it. Researchers describe the resulting state as deconstructed consciousness.
That is the mechanism. Not insight. Not catharsis. A temporary interruption of the process that assembles the sense of being someone, separate, here.
Where the research is
In October 2025 the U.S. Food and Drug Administration granted Breakthrough Therapy designation to BPL-003 — an intranasal formulation of mebufotenin (5-MeO-DMT) developed by Beckley Psytech and atai Life Sciences — for treatment-resistant depression. Following a successful End-of-Phase 2 meeting with the FDA, the company aligned on a two-study Phase 3 program.3The Usona Institute has completed a Phase 1 study of 5-MeO-DMT. GH Research is in Phase 2 with a 5-MeO compound for the same indication.4
In July 2026 Eli Lilly agreed to acquire the company developing it for approximately $2.8 billion, with up to $1 billion more tied to regulatory milestones. Initial Phase 3 results are expected around 2029.5
None of that is ours. It belongs to a pharmaceutical company, a specific formulation, and a specific clinical indication — a nasal spray, given in a clinic, for treatment-resistant depression. It makes no claim about what we do, and we are not going to pretend otherwise.
What it tells you is narrower, and it is the only thing we would ask you to take from it. The regulator no longer treats this molecule as fringe.
In their words
Nothing around me has changed, and I have changed quite a bit. The first thing that I've told close people around me is that it was like there was an emotional reset button, and I really mean that. Like a button or a switch that was just pressed.
I feel free. People have told me that I feel lighter around them.
What it requires
This molecule is powerful. It's fast. It's direct. And it requires responsibility, readiness, and respect.
Used recklessly, it can be overwhelming. Used ceremonially, it can be misdirected.
Used precisely — inside a container that prepares you before and holds you for months after — it reaches a layer nothing else reaches.
- Screened
- Contained
- Precise
- Short
What we don't pretend
5-MeO carries real contraindications. It interacts dangerously with MAOIs and with some psychiatric medications. It raises heart rate and blood pressure. A minority of people experience reactivations in the days that follow.
This is why eligibility is determined by a licensed physician, and not by us. It is why nobody reaches the day without clearing that first. And it is why anyone who tells you this is safe for everyone is selling you something.
Not everyone is medically eligible. Not everyone is at this point in the work.
If the knock is familiar, the next step is a conversation.
- Reckweg et al., "The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)," Journal of Neurochemistry, 2022. Two receptor-binding studies (Ray, 2010; Halberstadt et al., 2012) converge on 300–1000-fold selectivity for 5-HT1A over 5-HT2A.
- Timmermann C, Sanders JW, Reydellet D, et al., "Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness," Neuroscience of Consciousness, 2025(1): niaf007. An exploratory observational study conducted in naturalistic settings; the authors note its limitations.
- atai Life Sciences and Beckley Psytech, Breakthrough Therapy designation, 16 October 2025. AtaiBeckley, "Successful End-of-Phase 2 Meeting for BPL-003," 3 March 2026 (two-study Phase 3 program; initiation targeted Q2 2026).
- Psychedelic Health, 22 October 2025 (Usona Phase 1; GH Research Phase 2).
- Eli Lilly and Company, "Lilly to acquire AtaiBeckley," press release, 16 July 2026. A definitive agreement; the transaction had not closed at the time of writing.